osteoporosis
OSTEOPOROSIS
Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.

Differential Diagnosis

  • Pathological fracture
  • Secondary osteoporosis
Causes of Secondary Osteoporosis
  • Endocrine diseases [eg Cushing’s syndrome, hypogonadism (mostly in men), hyperthyroidism, hyperparathyroidism, type 1 or 2 diabetes, premature menopause, acromegaly, porphyria, growth hormone deficiency, etc]
  • Medications (eg corticosteroids, Heparin, anticonvulsants, immunosuppressants, aromatase inhibitors, gonadotropin-releasing hormone agents, proton pump inhibitors, Medroxyprogesterone, etc)
  • Chronic diseases (eg renal impairment, liver cirrhosis, malabsorption, rheumatoid arthritis, COPD, AIDS/HIV, ankylosing spondylitis, hemophilia, major depression, organ transplantation, Marfan syndrome, osteogenesis imperfecta, etc)
  • Others (eg malnutrition, malignancy, excessive alcohol, prolonged immobility, pregnancy, total parenteral nutrition,etc)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
5 days ago
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.
04 Jan 2017
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).